Neurons generated from stem cells (from skin fibroblasts) of a patient with sporadic Alzheimer’s disease. Visualized with a specific green fluorescent marker. Nuclei are shown in blue. Researchers ...
Researchers from the Institute for Neurosciences (IN), a joint center of the Miguel Hernández University of Elche (UMH) and the Spanish National Research Council (CSIC), who are also part of the ...
NEW YORK, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system ...
A molecular mechanism that significantly contributes to the progression of Alzheimer’s disease has been discovered by a research team led by neurobiologist Prof. Dr Hilmar Bading of Heidelberg ...
Aη, or A-eta, made an initial splash when scientists reported that these fragments of amyloid precursor protein—products of a heretofore unknown cleavage—dampen neural activity. But how? The story ...
Researchers identify neurotoxic protein complex and a pharmacological inhibitor that opens new perspectives for developing effective therapies A research group led by neurobiologist Prof. Dr. Hilmar B ...
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...
Agitation reported in nearly 50% of patients with Alzheimer’s disease FDA Fast Track designation previously received for AXS-05 for Alzheimer’s disease agitation Second indication for AXS-05 in ...
Otsuka Pharmaceutical is packing up an Alzheimer’s disease med after a phase 3 study failed to move the needle on measures of agitation associated with dementia. The results were originally issued in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback